MedTrace Logo

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

NCT00232193 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2011-07-22

No results posted yet for this study

Summary

The purpose of the study is to determine whether giving intravenous dexamethasone every 4 weeks during the first 12 months of weekly Avonex dosing will reduce the progression of functional impairment, brain atrophy, relapse rate and frequency, and new and enlarging brain lesions over the first 24 months of Avonex therapy in patients with relapsing-remitting or mono-symptomatic multiple sclerosis.

Conditions

  • Relapsing-remitting Multiple Sclerosis
  • Clinically Isolated Syndrome

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Providence Multiple Sclerosis Center

    lead OTHER

Principal Investigators

  • Stanley L. Cohan, M.D., Ph.D. · Providence Multiple Sclerosis Center

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2008-12-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232193 on ClinicalTrials.gov